TriVirum is a technology company.
TriVirum has raised $2.0M across 2 funding rounds.
TriVirum has raised $2.0M in total across 2 funding rounds.
TriVirum has raised $2.0M in total across 2 funding rounds.
TriVirum's investors include MMC Ventures, Northpond Ventures, Par Equity, Section 32.
TriVirum is an early-stage medical device company founded in 2018 (with some sources noting 2019) in Lincoln, California, that developed cost-effective sensors using semiconductor and signal processing technology to deliver actionable clinical data for improving patient outcomes and reducing healthcare costs[1][2][3][4]. Its flagship product, A-Fib-Chek, was a low-cost disposable wearable device designed for mass screening of atrial fibrillation (AFib) in populations aged 65+, targeting the estimated 25 million undiagnosed patients at risk of stroke[3]. The company served clinicians and health plans, solving the problem of undetected cardiac arrhythmias through superior test quality at lower costs, but raised $17.48M in seed funding before shutting down in late 2025 after failing to secure more capital[1][6].
TriVirum was founded by Tim Richter in 2018 (or 2019 per one source) in Lincoln, California, emerging from the need for affordable, high-quality medical sensors amid rising demands for early intervention in vulnerable populations[1][4]. The idea leveraged leading-edge semiconductor and signal processing technology to create innovative devices like A-Fib-Chek, addressing undiagnosed AFib as the leading cause of stroke[2][3]. Early traction included seed funding rounds totaling $17.48M from investors like Par Equity and Almond Tree Capital, with a $9.1M raise in early 2024, and filing two patents in cardiac electrophysiology and antiarrhythmic agents[1][3]. However, despite this momentum, the company exhausted funds and ceased operations by November 2025[6].
TriVirum stood out in the medtech space through these key strengths:
TriVirum rode the wave of wearable medtech and AI-driven diagnostics, capitalizing on trends in affordable, at-home cardiac monitoring amid aging populations and rising stroke risks from undiagnosed AFib[2][3]. Timing aligned with post-pandemic demand for cost-efficient telehealth tools and semiconductor advancements enabling miniaturized sensors, while market forces like healthcare cost pressures favored its low-price model[1][5]. Though it influenced early-stage validation of disposable arrhythmia detectors, its shutdown highlights funding challenges in medtech hardware amid investor caution on hardware scalability[6].
TriVirum's closure after $17M raised underscores the high-burn risks in early-stage medtech, leaving its A-Fib-Chek tech and patents potentially available for acquisition by larger players in cardiac monitoring[1][6]. Trends like AI-enhanced wearables and value-based care will likely propel similar innovations forward, but survivors must prove faster paths to reimbursement and scale. Its story ties back to the promise of semiconductor-driven health equity—unfulfilled here, yet priming the ecosystem for the next breakthrough in accessible AFib detection.
TriVirum has raised $2.0M across 2 funding rounds. Most recently, it raised $1.0M Venture Round in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $1.0M Venture Round | MMC Ventures, Northpond Ventures, Par Equity, Section 32 | |
| Aug 1, 2020 | $1.0M Seed | MMC Ventures, Northpond Ventures, Par Equity, Section 32 |